Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

Annals of the Rheumatic Diseases

Volumn 61, Issue 2, 2002, Pages 171-173

  Kietz, D A ^a   Pepmueller, P H ^a   Moore, T L ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HEMOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IDIOPATHIC DISEASE; JOINT STIFFNESS; JUVENILE RHEUMATOID ARTHRITIS; MALE; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0036151142     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.2.171     Document Type: Article

References (15)

1. Etanercept in children with polyarticular juvenile rheumatoid arthritis
2. Etanercept (Enbrel): Update on therapeutic use
3. Clinical response to etanercept in poly-articular course juvenile rheumatoid arthritis
4. Immunopathogenesis of juvenile rheumatoid arthritis
5. Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases
6. Cytokines in juvenile rheumatoid arthritis
7. Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis
8. Study of pro-inflammatory (TNF-α, IL-1α, IL-6) and T-cell derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters
9. Pattern of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptor in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy
10. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
11. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
12. Recombinant human dimeric tumor necrosis factor (TNF) receptor (TNF:Fc): Safety and pharmacokinetics in humans
13. Recombinant soluble tumor necrosis factor receptor (p75) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
14. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
15. Etanercept therapy in rheumatoid arthritis